Home › Companies › CRINETICS PHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and CRINETICS PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore CRINETICS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are CRINETICS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: R. Scott Struthers, Ph.D. | 69,586,919 | -- | -- | 15,729,147 | 3,615,529 | Majority: yes |
| Elect Director: Matthew K. Fust | 67,615,092 | -- | -- | 17,700,974 | 3,615,529 | Majority: yes |
| Elect Director: Rogério Vivaldi Coelho, M.D. | 68,864,528 | -- | -- | 16,451,538 | 3,615,529 | Majority: yes |
Source: CRINETICS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-12 — read the filing on EDGAR.
Each item below shows how the 247 asset managers that disclosed a CRINETICS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRINETICS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2025-06-11.
Combines 7 wordings of this item as funds reported it.
98% fund support · no official result
The 232 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 28,028,061 | 0 | 0 | 0 | For |
| Vanguard | 12,684,727 | 778 | 0 | 0 | For |
| T. Rowe Price | 9,634,777 | 0 | 0 | 0 | For |
| Wellington | 5,654,495 | 0 | 0 | 0 | For |
| BlackRock | 5,062,198 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,495,194 | 0 | 0 | 0 | For |
| State Street | 3,706,747 | 25,711 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 2,849,299 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,206,721 | 0 | 0 | 0 | For |
| Janus Henderson | 1,907,371 | 4,417 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 1,854,208 | 2,682 | 0 | 0 | For |
| Siren, L.L.C. | 1,688,611 | 0 | 0 | 0 | For |
| Charles Schwab | 1,526,765 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 1,494,974 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,275,000 | 0 | 0 | 0 | For |
| American Century | 0 | 1,243,887 | 0 | 0 | Against |
| Prudential/PGIM | 1,150,042 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,148,500 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,088,848 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 1,009,079 | 5,952 | 0 | 0 | For |
| Vestal Point Capital, LP | 951,565 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 927,328 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 901,769 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 837,932 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 821,314 | 0 | 0 | 0 | For |
Showing the 25 largest of 232 asset managers. See all 232 in the interactive database.
Meeting held 2025-06-11.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Matthew K. Fust”): 67,615,092 for, 17,700,974 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,525,000 outstanding shares: 72% for, 19% withheld (91% of the company cast a for/withheld vote).
The 73 asset managers below cast 100% of the shares they voted on this item FOR (39,700,678 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,100,477 | 0 | 0 | 0 | For |
| Vanguard | 12,386,585 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,083,567 | 0 | 0 | 0 | For |
| BlackRock | 2,807,048 | 0 | 0 | 0 | For |
| Prudential/PGIM | 991,701 | 0 | 152,686 | 0 | For |
| State Street | 1,138,130 | 0 | 1,441 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 1,088,848 | 0 | Abstain |
| Bridge Builder Trust | 17,922 | 0 | 997,109 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 901,769 | 0 | Abstain |
| Charles Schwab | 763,288 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 607,646 | 0 | Abstain |
| Manager Directed Portfolios | 466,010 | 0 | 0 | 0 | For |
| TIAA | 405,093 | 0 | 0 | 0 | For |
| Hartford | 397,744 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,515 | 0 | 338,801 | 0 | Abstain |
| Aberdeen | 0 | 0 | 280,347 | 0 | Abstain |
| Victory Capital | 829 | 0 | 273,922 | 0 | Abstain |
| Equitable | 160,600 | 0 | 99,820 | 0 | For |
| John Hancock | 198,005 | 0 | 50,369 | 0 | For |
| Voya | 245,997 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 228,926 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 188,805 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 173,541 | 0 | Abstain |
| New York Life | 91,278 | 0 | 47,847 | 0 | For |
| Brighthouse | 86,578 | 0 | 44,472 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Meeting held 2025-06-11.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: R. Scott Struthers, Ph.D.”): 69,586,919 for, 15,729,147 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,525,000 outstanding shares: 74% for, 17% withheld (91% of the company cast a for/withheld vote).
The 73 asset managers below cast 100% of the shares they voted on this item FOR (40,377,941 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,100,477 | 0 | 0 | 0 | For |
| Vanguard | 12,386,585 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,083,567 | 0 | 0 | 0 | For |
| BlackRock | 2,807,048 | 0 | 0 | 0 | For |
| Prudential/PGIM | 991,701 | 0 | 152,686 | 0 | For |
| State Street | 1,138,130 | 0 | 1,441 | 0 | For |
| JANUS INVESTMENT FUND | 755,632 | 0 | 333,216 | 0 | For |
| Bridge Builder Trust | 17,922 | 0 | 997,109 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 901,769 | 0 | Abstain |
| Charles Schwab | 763,288 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 607,646 | 0 | Abstain |
| Manager Directed Portfolios | 466,010 | 0 | 0 | 0 | For |
| TIAA | 405,093 | 0 | 0 | 0 | For |
| Hartford | 397,744 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,515 | 0 | 338,801 | 0 | Abstain |
| Aberdeen | 0 | 0 | 280,347 | 0 | Abstain |
| Victory Capital | 829 | 0 | 273,922 | 0 | Abstain |
| Equitable | 260,420 | 0 | 0 | 0 | For |
| John Hancock | 198,005 | 0 | 50,369 | 0 | For |
| Voya | 0 | 0 | 245,997 | 0 | Abstain |
| FRANKLIN STRATEGIC SERIES | 228,926 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 188,805 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 173,541 | 0 | Abstain |
| New York Life | 91,278 | 0 | 47,847 | 0 | For |
| Brighthouse | 86,578 | 0 | 44,472 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Meeting held 2025-06-11.
Combines 9 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Rogério Vivaldi Coelho, M.D.”): 68,864,528 for, 16,451,538 withheld, per its Form 8-K filed 2025-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 93,525,000 outstanding shares: 74% for, 18% withheld (91% of the company cast a for/withheld vote).
The 73 asset managers below cast 100% of the shares they voted on this item FOR (39,758,789 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,100,477 | 0 | 0 | 0 | For |
| Vanguard | 12,386,585 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,083,567 | 0 | 0 | 0 | For |
| BlackRock | 2,807,048 | 0 | 0 | 0 | For |
| Prudential/PGIM | 991,701 | 0 | 152,686 | 0 | For |
| State Street | 1,138,130 | 0 | 1,441 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 1,088,848 | 0 | Abstain |
| Bridge Builder Trust | 17,922 | 0 | 997,109 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 901,769 | 0 | Abstain |
| Charles Schwab | 763,288 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 607,646 | 0 | Abstain |
| Manager Directed Portfolios | 466,010 | 0 | 0 | 0 | For |
| TIAA | 405,093 | 0 | 0 | 0 | For |
| Hartford | 397,744 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,515 | 0 | 338,801 | 0 | Abstain |
| Aberdeen | 0 | 0 | 280,347 | 0 | Abstain |
| Victory Capital | 829 | 0 | 273,922 | 0 | Abstain |
| Equitable | 160,600 | 0 | 99,820 | 0 | For |
| John Hancock | 198,005 | 0 | 50,369 | 0 | For |
| Voya | 245,997 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 228,926 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 188,805 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 173,541 | 0 | Abstain |
| New York Life | 91,278 | 0 | 47,847 | 0 | For |
| Brighthouse | 86,578 | 0 | 44,472 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Meeting held 2025-06-11.
Combines 2 wordings of this item as funds reported it.
99.9% fund support · no official result
The 70 asset managers below cast 99.9% of the shares they voted on this item FOR (45,468,231 for, 636 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 14,100,477 | 0 | 0 | 0 | For |
| Vanguard | 12,386,585 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,083,567 | 0 | 0 | 0 | For |
| BlackRock | 2,807,048 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,144,387 | 0 | 0 | 0 | For |
| State Street | 1,139,514 | 57 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,088,848 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 1,015,031 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 901,769 | 0 | 0 | 0 | For |
| Charles Schwab | 763,288 | 0 | 0 | 0 | For |
| American Century | 607,646 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 466,010 | 0 | 0 | 0 | For |
| TIAA | 405,093 | 0 | 0 | 0 | For |
| Hartford | 397,744 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 341,316 | 0 | 0 | 0 | For |
| Aberdeen | 280,347 | 0 | 0 | 0 | For |
| Victory Capital | 274,751 | 0 | 0 | 0 | For |
| Equitable | 260,420 | 0 | 0 | 0 | For |
| John Hancock | 248,374 | 0 | 0 | 0 | For |
| Voya | 245,997 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 228,926 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 188,805 | 0 | 0 | 0 | For |
| Jackson National | 173,541 | 0 | 0 | 0 | For |
| New York Life | 139,125 | 0 | 0 | 0 | For |
| Brighthouse | 123,292 | 0 | 7,758 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-06-11.
Combines 2 wordings of this item as funds reported it.
68% fund support · no official result
The 6 asset managers below cast 68% of the shares they voted on this item FOR (239,965 for, 112,940 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 234,956 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 0 | 112,485 | 0 | 0 | Against |
| Maj Invest Holding A/S | 4,838 | 0 | 0 | 0 | For |
| HC CAPITAL TRUST | 0 | 455 | 0 | 0 | Against |
| TD ASSET MANAGEMENT INC | 150 | 0 | 0 | 0 | For |
| UNIFIED SERIES TRUST | 21 | 0 | 0 | 0 | For |
Meeting held 2025-06-11.
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (98,873 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Pier Capital, LLC | 70,439 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 17,360 | 0 | 0 | 0 | For |
| Dunham Funds | 11,074 | 0 | 0 | 0 | For |
Meeting held 2024-06-07 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
0% fund support · no official result
The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 116 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| COLDSTREAM CAPITAL MANAGEMENT INC | 0 | 116 | 0 | 0 | Against |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Meeting held 2025-06-11.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (28,434 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RBB FUND, INC. | 17,360 | 0 | 0 | 0 | For |
| Dunham Funds | 11,074 | 0 | 0 | 0 | For |
Meeting held 2025-06-11.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (476 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| HC CAPITAL TRUST | 455 | 0 | 0 | 0 | For |
| UNIFIED SERIES TRUST | 21 | 0 | 0 | 0 | For |
Ranked by the number of CRINETICS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 93,525,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 29.97% |
| 2 | Vanguard | 13.56% |
| 3 | T. Rowe Price | 10.30% |
| 4 | Wellington | 6.05% |
| 5 | BlackRock | 5.41% |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.81% |
| 7 | State Street | 3.99% |
| 8 | FARALLON CAPITAL MANAGEMENT LLC | 3.05% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.36% |
| 10 | Janus Henderson | 2.04% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 15.00% | 13F |
| Vanguard Group | 9.96% | 13F |
| Farallon Partners, L.L.C. | 8.37% | 13G |
| BlackRock | 8.19% | 13F |
| Wellington Management | 7.37% | 13F |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6.84% | 13G |
| T. Rowe Price | 5.47% | 13F |
| State Street | 3.51% | 13F |
| Franklin Templeton | 1.03% | 13F |
| Northern Trust | 0.92% | 13F |
Percentages above are of 93,525,000 shares outstanding, as reported by CRINETICS PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRINETICS PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At CRINETICS PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-11, in the 2024-2025 proxy season, 247 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,760 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. CRINETICS PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To consider and vote upon, on an advisory basis, the compensation of the Company's named… — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.
CRINETICS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.